Edward H Gunst Professor of Critical Care University of Georgia Athens, Georgia, United States
Disclosure(s):
Benjamin M. Brainard, VMD, DAVCAA, DACVECC: No financial relationships to disclose
Presentation Description / Summary: This lecture will discuss recent data on the use of new oral antithrombotics such as apixaban and rivaroxaban in veterinary medicine, with reference to specific use scenarios and the CURATIVE guidelines
Learner Outcomes: 1. understanding the current dosing and usage patterns reported for rivaroxaban and apixiaban 2. understand how to safely use of the oral anti-Xa drugs in cats and dogs 3. discuss how the oral anti-Xa drugs fit into an overall anticoagulant regimen
Learning Objectives:
Understand the differences between newer anti-Xa drugs and heparins
Examine the evidence behind various dosing structures for novel oral anti thrombotics
Apply the existing data to devise treatment plans for their own patients
